Comparison of Two Ultrasmall Superparamagnetic Iron Oxides on Cytotoxicity and MR Imaging of Tumors

Overview

Journal Theranostics

Date 2012 Jan 25

PMID 22272221

Citations 18

Authors

Mulan Li

Hoe Suk Kim

Lianji Tian

Mi Kyung Yu

Sangyong Jon

Woo Kyung Moon

Affiliations

Soon will be listed here.

Abstract

Purpose: This study was performed to compare the cytotoxicity and magnetic resonance (MR) contrast in diverse cultured cells and xenograft tumors models of two ultra-small superparamagnetic iron oxides (USPIOs), thermally cross-linked superparamagnetic iron oxide nanoparticles (TCL-SPION) and monocrystalline iron oxide nanoparticles (MION-47).

Materials And Methods: Transmission electron microscopy (TEM) images and R(2) relaxivity values of the TCL-SPION and MION-47 were obtained and the cell viability and cell growth velocity of treated and untreated human fibroblasts and human umbilical vein endothelial cells (HUVEC) were evaluated. The effect of TCL-SPION and MION-47 on the secretion of interlukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α), the production of nitric oxides and the mitochondrial membrane potentials in murine macrophage cells (RAW264.7) was compared. Human hepatocellular carcinoma cells (HepG2, 5x10(5)) were subcutaneously injected into nude mice (BALB/c) and in vivo MR imaging of tumors before and after injection with TCL-SPION or MION-47 (12.5 mg Fe/kg) was performed on a 1.5 Tesla MRI scanner.

Results: On TEM images, the average core diameter of TCL-SPION was 9 nm whereas that of MION-47 was 5 nm. TCL- SPION (345.0 ± 6.2 mM(-1)sec(-1)) had higher relaxivity (R(2)) than MION-47 (130.7 ± 1.1 mM(-1)sec(-1)). Significant changes in cell viability and growth were not found in human fibroblasts and HUVEC exposed to TCL-SPION and MION-47. However, IL-6 and TNF-α secretions increased dose-dependently and significantly in the macrophages treated with MION-47 or TCL-SPION. TCL-SPION had a lower stimulatory effect on IL-6 secretions than did MION-47 (P <0.05) and nitric oxides were produced in the macrophages by MION-47 but not TCL-SPION. A change in the mitochondrial membrane potential of the macrophages was observed 24 hours after the exposure, and MION-47 induced more collapses of the mitochondrial membrane potential than did TCL-SPION. In the in vivo MR imaging, 33.0 ± 1.3% and 7.5 ± 0.4% signal intensity decrease on T(2)*-weighted images was observed in the tumors injected with TCL-SPION and MION-47, respectively.

Conclusion: Due to the modified surface properties and larger core size of its iron oxide nanoparticles, TCL-SPION achieves lower cytotoxicity and better tumor MR contrast than MION-47. Our study suggests that TCL-SPION may be used as a new platform for tumor imaging and therapy monitoring.

Citing Articles

Janus USPION modular platform (JUMP) for theranostic ultrasound-mediated targeted intratumoral microvascular imaging and DNA/miRNA delivery.

Whitaker R, Decano J, Gormley C, Beigie C, Meisel C, Tan G Theranostics. 2022; 12(18):7646-7667.

PMID: 36451861 PMC: 9706579. DOI: 10.7150/thno.78454.

Nanoparticle Effects on Stress Response Pathways and Nanoparticle-Protein Interactions.

Cameron S, Sheng J, Hosseinian F, Willmore W Int J Mol Sci. 2022; 23(14).

PMID: 35887304 PMC: 9323783. DOI: 10.3390/ijms23147962.

Nanocarriers Used in Drug Delivery to Enhance Immune System in Cancer Therapy.

Lobo G, Paiva K, Silva A, Simoes M, Radicchi M, Bao S Pharmaceutics. 2021; 13(8).

PMID: 34452128 PMC: 8399799. DOI: 10.3390/pharmaceutics13081167.

Theranostics for Breast Cancer Stem Cells.

Moon W, Kim H Adv Exp Med Biol. 2021; 1187:267-281.

PMID: 33983583 DOI: 10.1007/978-981-32-9620-6_13.

Ultra-high field (10.5 T) resting state fMRI in the macaque.

Yacoub E, Grier M, Auerbach E, Lagore R, Harel N, Adriany G Neuroimage. 2020; 223:117349.

PMID: 32898683 PMC: 7745777. DOI: 10.1016/j.neuroimage.2020.117349.

References

Peer D, Karp J, Hong S, Farokhzad O, Margalit R, Langer R . Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2008; 2(12):751-60. DOI: 10.1038/nnano.2007.387. View

Lim S, Kim H, Jun H, Park S, Yoon K, Kim H . TCL-SPION-enhanced MRI for the detection of lymph node metastasis in murine experimental model. Acad Radiol. 2011; 18(4):504-11. DOI: 10.1016/j.acra.2010.10.017. View

Pestka S, Langer J, Zoon K, Samuel C . Interferons and their actions. Annu Rev Biochem. 1987; 56:727-77. DOI: 10.1146/annurev.bi.56.070187.003455. View

Wunderbaldinger P, Josephson L, Weissleder R . Crosslinked iron oxides (CLIO): a new platform for the development of targeted MR contrast agents. Acad Radiol. 2002; 9 Suppl 2:S304-6. DOI: 10.1016/s1076-6332(03)80210-6. View

Corot C, Robert P, Idee J, Port M . Recent advances in iron oxide nanocrystal technology for medical imaging. Adv Drug Deliv Rev. 2006; 58(14):1471-504. DOI: 10.1016/j.addr.2006.09.013. View

Sun R, Dittrich J, Le-Huu M, Mueller M, Bedke J, Kartenbeck J . Physical and biological characterization of superparamagnetic iron oxide- and ultrasmall superparamagnetic iron oxide-labeled cells: a comparison. Invest Radiol. 2005; 40(8):504-13. DOI: 10.1097/01.rli.0000162925.26703.3a. View

Apopa P, Qian Y, Shao R, Guo N, Schwegler-Berry D, Pacurari M . Iron oxide nanoparticles induce human microvascular endothelial cell permeability through reactive oxygen species production and microtubule remodeling. Part Fibre Toxicol. 2009; 6:1. PMC: 2632982. DOI: 10.1186/1743-8977-6-1. View

Benderbous S, Corot C, Jacobs P, Bonnemain B . Superparamagnetic agents: physicochemical characteristics and preclinical imaging evaluation. Acad Radiol. 1996; 3 Suppl 2:S292-4. DOI: 10.1016/s1076-6332(96)80560-5. View

Lee H, Yu M, Park S, Moon S, Min J, Jeong Y . Thermally cross-linked superparamagnetic iron oxide nanoparticles: synthesis and application as a dual imaging probe for cancer in vivo. J Am Chem Soc. 2007; 129(42):12739-45. DOI: 10.1021/ja072210i. View

10.

Maeda H . The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul. 2001; 41:189-207. DOI: 10.1016/s0065-2571(00)00013-3. View

11.

Keenan C, Goth-Goldstein R, Lucas D, Sedlak D . Oxidative stress induced by zero-valent iron nanoparticles and Fe(II) in human bronchial epithelial cells. Environ Sci Technol. 2009; 43(12):4555-60. DOI: 10.1021/es9006383. View

12.

Kim H, Choi Y, Song I, Moon W . Magnetic resonance imaging and biological properties of pancreatic islets labeled with iron oxide nanoparticles. NMR Biomed. 2009; 22(8):852-6. DOI: 10.1002/nbm.1398. View

13.

Huang P, Li Z, Lin J, Yang D, Gao G, Xu C . Photosensitizer-conjugated magnetic nanoparticles for in vivo simultaneous magnetofluorescent imaging and targeting therapy. Biomaterials. 2011; 32(13):3447-58. DOI: 10.1016/j.biomaterials.2011.01.032. View

14.

Lee H, Lee E, Kim D, Jang N, Jeong Y, Jon S . Antibiofouling polymer-coated superparamagnetic iron oxide nanoparticles as potential magnetic resonance contrast agents for in vivo cancer imaging. J Am Chem Soc. 2006; 128(22):7383-9. DOI: 10.1021/ja061529k. View

15.

Gupta A, Gupta M . Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials. 2005; 26(18):3995-4021. DOI: 10.1016/j.biomaterials.2004.10.012. View

16.

Namgung R, Singha K, Yu M, Jon S, Kim Y, Ahn Y . Hybrid superparamagnetic iron oxide nanoparticle-branched polyethylenimine magnetoplexes for gene transfection of vascular endothelial cells. Biomaterials. 2010; 31(14):4204-13. DOI: 10.1016/j.biomaterials.2010.01.123. View

17.

Kim H, Oh S, Joo H, Son K, Song I, Moon W . The effects of clinically used MRI contrast agents on the biological properties of human mesenchymal stem cells. NMR Biomed. 2010; 23(5):514-22. DOI: 10.1002/nbm.1487. View

18.

Wang Y, Hussain S, Krestin G . Superparamagnetic iron oxide contrast agents: physicochemical characteristics and applications in MR imaging. Eur Radiol. 2001; 11(11):2319-31. DOI: 10.1007/s003300100908. View

19.

Yu M, Park J, Jeong Y, Moon W, Jon S . Integrin-targeting thermally cross-linked superparamagnetic iron oxide nanoparticles for combined cancer imaging and drug delivery. Nanotechnology. 2010; 21(41):415102. DOI: 10.1088/0957-4484/21/41/415102. View

20.

Shen T, Weissleder R, Papisov M, Bogdanov Jr A, Brady T . Monocrystalline iron oxide nanocompounds (MION): physicochemical properties. Magn Reson Med. 1993; 29(5):599-604. DOI: 10.1002/mrm.1910290504. View